<DOC>
	<DOC>NCT03063749</DOC>
	<brief_summary>To observe the continued performance of the Medtronic Resolute Onyxâ„¢ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.</brief_summary>
	<brief_title>RESOLUTE ONYX Post-Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Key Inclusion Criteria Symptomatic coronary artery disease including subjects with chronic stable angina, silent ischemia, and acute coronary syndromes including nonST elevation and STelevation myocardial infarction Subject is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use, and the Declaration of Helsinki Key Exclusion Criteria Unprotected left main disease Subjects with planned PCI of three vessel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>